drugset / Trial / NCT00043407
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
CPG 7909 given alone to patients with renal cell cancer after their nephrectomy. CPG 7909 is as a subcutaneous injection once per week for up to 24 weeks. Up to 40 patients will be included in the study.
Timeline
- Start
- 2002-03
- Primary completion
- 2004-09
- Completion
- 2004-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | agatolimod | Oligonucleotide (other) | 0.08 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.12 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.16 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.36 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.54 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.81 mg/kg | Subcutaneous |